Published in Front Oncol on February 22, 2017
Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. Oncoimmunology (2017) 0.75
Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy. Oncotarget (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Immunity, inflammation, and cancer. Cell (2010) 28.27
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science (2012) 8.42
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 6.70
Circuitry of nuclear factor kappaB signaling. Immunol Rev (2006) 6.49
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest (2005) 5.90
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA (1998) 5.09
The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer (2005) 5.07
Lipid signalling in disease. Nat Rev Mol Cell Biol (2008) 4.85
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev (2006) 4.61
Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 4.44
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell (1999) 4.32
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
Tissue-resident macrophages. Nat Immunol (2013) 4.09
Regulation of immune responses by prostaglandin E2. J Immunol (2012) 3.93
The cellular and molecular origin of tumor-associated macrophages. Science (2014) 3.89
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol (2002) 3.82
Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer (2014) 3.70
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Regulation of immune responses by extracellular vesicles. Nat Rev Immunol (2014) 3.24
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03
Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A (2010) 2.94
Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity (2009) 2.84
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol (2005) 2.81
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature (2013) 2.78
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 2.76
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci U S A (2005) 2.74
Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol (2006) 2.67
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol (2007) 2.65
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell (2015) 2.60
TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell (2009) 2.53
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol (2015) 2.52
The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 2.48
Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci U S A (2000) 2.36
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res (2008) 2.35
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 2.26
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 2.18
Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat Immunol (2005) 2.18
Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer (2005) 2.17
Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer (2008) 2.06
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res (2003) 2.06
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol (2004) 2.05
Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res (1995) 2.05
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev (2008) 1.96
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science (2014) 1.94
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res (1997) 1.94
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 1.93
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst (2014) 1.93
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest (1995) 1.91
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res (1993) 1.90
Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov (2011) 1.88
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87
Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.87
Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene (2010) 1.86
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett (2009) 1.84
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood (2007) 1.83
Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol (2015) 1.79
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol (1997) 1.79
Lysophospholipids activate ovarian and breast cancer cells. Biochem J (1995) 1.76
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol (1996) 1.74
Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer (1997) 1.72
Antigen Loss Variants: Catching Hold of Escaping Foes. Front Immunol (2017) 0.75